209 related articles for article (PubMed ID: 31205516)
1. The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer.
Yoon SE; Lee SJ; Lee J; Park SH; Park JO; Lim HY; Kang WK; Park YS; Kim ST
J Cancer; 2019; 10(7):1611-1615. PubMed ID: 31205516
[TBL] [Abstract][Full Text] [Related]
2. Factors Affecting the Efficacy of Regorafenib in Metastatic Colorectal Cancer: Is Tumour Sidedness Important?
Kazaz SN; Ozdover AC; Usta N; Yildirim A; Fidan E; Ozdemir F
J Coll Physicians Surg Pak; 2023 Jun; 33(6):659-665. PubMed ID: 37300262
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer.
Kim ST; Lee SJ; Lee J; Park SH; Park JO; Lim HY; Kang WK; Park YS
J Cancer; 2017; 8(14):2809-2815. PubMed ID: 28928870
[No Abstract] [Full Text] [Related]
4. [Comparison of clinicopathological features and prognosis between left-sided colon cancer and right-sided colon cancer].
Gao X; Yu G; Liu P; Hao L; Liu L; Zhang W
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Jun; 20(6):647-653. PubMed ID: 28643309
[TBL] [Abstract][Full Text] [Related]
5. The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer.
Kim ST; Kim HK; Lee J; Park SH; Lim HY; Park YS; Kang WK; Park JO
J Cancer; 2018; 9(10):1791-1796. PubMed ID: 29805705
[No Abstract] [Full Text] [Related]
6. Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location.
Sasaki K; Margonis GA; Wilson A; Kim Y; Buettner S; Andreatos N; Gani F; Amini N; Spolverato G; Pawlik TM
Ann Surg Oncol; 2016 Oct; 23(11):3736-3743. PubMed ID: 27352204
[TBL] [Abstract][Full Text] [Related]
7. Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO.
Cremolini C; Antoniotti C; Lonardi S; Bergamo F; Cortesi E; Tomasello G; Moretto R; Ronzoni M; Racca P; Loupakis F; Zaniboni A; Tonini G; Buonadonna A; Marmorino F; Allegrini G; Granetto C; Masi G; Zagonel V; Sensi E; Fontanini G; Boni L; Falcone A
Ann Oncol; 2018 Jul; 29(7):1528-1534. PubMed ID: 29873679
[TBL] [Abstract][Full Text] [Related]
8. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.
Brulé SY; Jonker DJ; Karapetis CS; O'Callaghan CJ; Moore MJ; Wong R; Tebbutt NC; Underhill C; Yip D; Zalcberg JR; Tu D; Goodwin RA
Eur J Cancer; 2015 Jul; 51(11):1405-14. PubMed ID: 25979833
[TBL] [Abstract][Full Text] [Related]
9. [Difference analysis of chemotherapy efficacy among different primary tumor sites in metastatic colorectal cancer].
Sun Z; Wang X; Jia J; Liu C; Zhang X; Shen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Oct; 19(10):1119-1123. PubMed ID: 27781247
[TBL] [Abstract][Full Text] [Related]
10. Primary tumor location and survival in colorectal cancer: A retrospective cohort study.
Aggarwal H; Sheffield KM; Li L; Lenis D; Sorg R; Barzi A; Miksad R
World J Gastrointest Oncol; 2020 Apr; 12(4):405-423. PubMed ID: 32368319
[TBL] [Abstract][Full Text] [Related]
11. Effect of Primary Tumor Location on Second- or Later-Line Treatment With Anti-Epidermal Growth Factor Receptor Antibodies in Patients With Metastatic Colorectal Cancer: A Retrospective Multi-Center Study.
Archwamety A; Teeyapun N; Siripoon T; Poungvarin N; Tanasanvimon S; Sirachainan E; Akewanlop C; Korphaisarn K
Front Oncol; 2022; 12():813009. PubMed ID: 35242708
[TBL] [Abstract][Full Text] [Related]
12. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
[TBL] [Abstract][Full Text] [Related]
13. The impact of primary tumor sidedness on survival in early-onset colorectal cancer by stage: A National Veterans Affairs retrospective analysis.
Azar I; Al Masalmeh N; Esfandiarifard S; Virk G; Kiwan W; Frank Shields A; Mehdi S; Philip PA
Cancer Med; 2021 May; 10(9):2987-2995. PubMed ID: 33797856
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients.
Salvatore L; Bensi M; Vivolo R; Zurlo IV; Dell'Aquila E; Grande R; Anghelone A; Emiliani A; Citarella F; Calegari MA; Ribelli M; Basso M; Pozzo C; Tortora G
Front Oncol; 2023; 13():1125013. PubMed ID: 36895480
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials.
Sunakawa Y; Ichikawa W; Tsuji A; Denda T; Segawa Y; Negoro Y; Shimada K; Kochi M; Nakamura M; Kotaka M; Tanioka H; Takagane A; Tani S; Yamaguchi T; Watanabe T; Takeuchi M; Fujii M; Nakajima T
Clin Colorectal Cancer; 2017 Sep; 16(3):e171-e180. PubMed ID: 27856123
[TBL] [Abstract][Full Text] [Related]
16. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
[TBL] [Abstract][Full Text] [Related]
17. Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment.
Lee MS; Cho HJ; Hong JY; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Cho YB; Kim ST
Ther Adv Med Oncol; 2020; 12():1758835920965842. PubMed ID: 33224274
[TBL] [Abstract][Full Text] [Related]
18. Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting.
Ma CJ; Huang CW; Chang TK; Tsai HL; Su WC; Yeh YS; Chen PJ; Wang JY
Transl Oncol; 2019 Mar; 12(3):502-512. PubMed ID: 30594039
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Primary Tumor Sidedness for Unresectable Stage IV Colorectal Cancer: A Retrospective Study.
Shida D; Tanabe T; Boku N; Takashima A; Yoshida T; Tsukamoto S; Kanemitsu Y
Ann Surg Oncol; 2019 May; 26(5):1358-1365. PubMed ID: 30719633
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of raltitrexed plus S-1
Zhou YW; Wang JL; Li QF; He YL; Li LJ; Liu RZ; Chen Y; Zhang S; Qiu M; Liu JY
Therap Adv Gastroenterol; 2022; 15():17562848221098246. PubMed ID: 35601804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]